Study guide
4.5 Pharmacotherapy for Anorexia-Cachexia Syndrome & Orexigenics
CDR CSO Board Certified Specialist in Oncology Nutrition Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the CDR CSO Exam & Certification Logistics 1.2 How to Navigate and Master This Study Guide
2 Chapter 2: Cancer & Cancer Treatment Modalities
2.1 Cancer Biology, Pathophysiology, & Carcinogenesis 2.2 Staging, Grading, & Surgical Oncology Interventions 2.3 Radiation Therapy Modalities & Radiation Toxicities 2.4 Cytotoxic Chemotherapy & Emetogenic Risk Staging 2.5 Targeted Therapies, Immunotherapies, & CAR-T Cell Therapy 2.6 Hematopoietic Stem Cell Transplantation (HSCT/BMT)
3 Chapter 3: Comprehensive Nutrition Assessment & Malnutrition Staging
3.1 Patient-Generated Subjective Global Assessment (PG-SGA) 3.2 GLIM Criteria for Malnutrition Diagnosis in Oncology 3.3 Cancer Cachexia Staging & Pathophysiology (Fearon Consensus) 3.4 Estimating Energy & Protein Requirements (ESPEN Guidelines) 3.5 Anthropometrics & Body Composition Analysis (DEXA, BIA, CT) 3.6 Biochemical & Inflammatory Marker Interpretation 3.7 Nutrition-Focused Physical Exam (NFPE) in Oncology 3.8 Medical, Oncologic, and Treatment History Review 3.9 Diet and Lifestyle History: Methods and Interpretation 3.10 Cultural, Psychosocial, and Socioeconomic Factors
4 Chapter 4: Nutrition-Impact Side Effect Management & Pharmacotherapy
4.1 Upper GI Symptoms: Anorexia, Early Satiety, Nausea, & Vomiting 4.2 Oral & Mucosal Toxicities: Stomatitis, Mucositis, Dysgeusia, & Xerostomia 4.3 Lower GI Toxicities: Diarrhea, Radiation Enteritis, & Constipation 4.4 Pancreatic Exocrine Insufficiency & PERT Dosing Protocols 4.5 Pharmacotherapy for Anorexia-Cachexia Syndrome & Orexigenics 4.6 Oncologic Emergencies: Tumor Lysis, Hypercalcemia, & Superior Vena Cava Syndrome
5 Chapter 5: Specialized Nutrition Interventions, Disease-Site MNT & Care Coordination
5.1 Enteral Nutrition: Access, Indications, & Formula Selection 5.2 Prophylactic Enteral Tubes in Head & Neck Cancer 5.3 Parenteral Nutrition in Oncology: Indications & Management 5.4 Disease-Site MNT: Head & Neck, Esophageal, & Gastric Cancers 5.5 Disease-Site MNT: Pancreatic, Hepatobiliary, & Colorectal Cancers 5.6 Disease-Site MNT: Hematologic Malignancies & HSCT 5.7 Refeeding Syndrome & Cyclic Nutrition Support Protocols 5.8 Referrals, Care Coordination, and Transitions of Care 5.9 Monitoring, Evaluation, and Nutrition Outcomes
6 Chapter 6: Patient Education, Counseling, & Herbal/Supplement Safety
6.1 Patient Counseling & Motivational Interviewing 6.2 Managing Sensory Alterations & Taste Changes 6.3 Complementary & Alternative Medicine (CAM) in Oncology 6.4 Dietary Supplement & Herbal Safety during Cancer Therapy 6.5 Key Drug-Nutrient Interactions in Oncology
7 Chapter 7: Cancer Survivorship, Palliative Nutrition, & End-of-Life Ethics
7.1 Food Safety & Neutropenic Dietary Evidence 7.2 Cancer Survivorship: AICR/WCRF Guidelines & Lifestyle 7.3 Weight Management & Metabolic Health in Survivorship 7.4 Palliative Nutrition & Goals of Care Alignment 7.5 End-of-Life Ethical Considerations & Bioethics
4.5 Pharmacotherapy for Anorexia-Cachexia Syndrome & Orexigenics
Key Takeaways Explain This Topic AI
Cancer Anorexia-Cachexia Syndrome (CACS) is a multi-factorial metabolic syndrome driven by pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) causing ongoing skeletal muscle proteolysis that cannot be fully reversed by conventional nutrition support alone.
Megestrol acetate (400-800 mg/day) improves appetite and body weight, but weight gain consists almost entirely of adipose tissue and fluid retention (not muscle mass), and carries high risks of DVT/PE and adrenal suppression.
Corticosteroids (dexamethasone 4 mg/day) provide rapid short-term appetite stimulation but must be strictly limited to <2-3 weeks due to severe long-term risks of steroid-induced myopathy (accelerating muscle loss), hyperglycemia, and immunosuppression.
Mirtazapine (15-30 mg at bedtime) targets the triad of anorexia, depression, and insomnia, while Olanzapine (5 mg daily) acts via multi-receptor blockade to improve appetite, promote weight gain, and reduce nausea.
Last updated: August 2026
4.5 Pharmacotherapy for Anorexia-Cachexia Syndrome & Orexigenics
Cancer Anorexia-Cachexia Syndrome (CACS) is a complex, multi-factorial metabolic syndrome characterized by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support alone, leading to progressive functional impairment, diminished quality of life, reduced treatment tolerance, and shortened survival. CACS affects up to 80% of patients with advanced solid tumors (particularly pancreatic, gastric, non-small cell lung, and head and neck cancers). Effective clinical management mandates combining orexigenic pharmacotherapy with high-protein Medical Nutrition Therapy (MNT).
- Diagnostic Staging & Pathophysiology of CACS
- International Diagnostic Staging Framework
According to international consensus criteria (Fearon et al.), CACS progresses through three clinical stages:
Pre-cachexia: Involuntary weight loss ≤ 5 % \le 5\% ≤ 5% over 6 months, accompanied by anorexia and systemic metabolic or inflammatory alterations.
Cachexia: Involuntary weight loss > 5 % >5\% > 5% over 6 months, OR BMI < 20 kg/m 2 <20\text{ kg/m}^2 < 20 kg/m 2 with weight loss > 2 % >2\% > 2% , OR sarcopenia (loss of skeletal muscle mass) with weight loss > 2 % >2\% > 2% . Reduced food intake and systemic inflammation are present.
Refractory Cachexia: Advanced catabolic state driven by highly aggressive tumor biology; ECOG performance status 3–4; unmodifiable catabolism; estimated life expectancy < 3 <3 < 3 months.
Molecular Mechanisms & Cytokine Cascade
Unlike simple starvation (where the body adaptively conserves muscle mass and hydrolyzes primary fat stores), CACS is driven by systemic inflammation and tumor-host interactions:
Pro-inflammatory Cytokines: Tumor and host immune cells release Tumor Necrosis Factor-alpha (TNF- α \alpha α / cachectin) , Interleukin-6 (IL-6) , Interleukin-1 beta (IL-1 β \beta β ) , and Interferon-gamma (IFN- γ \gamma γ ) .
Muscle Proteolysis: Cytokines activate the Ubiquitin-Proteasome System (UPS) and autophagy pathways in skeletal muscle, degrading myofibrillar proteins (actin and myosin).
Hypothalamic Anorexia: Cytokines downregulate orexigenic neuropeptides ( Neuropeptide Y [NPY] and Agouti-Related Peptide [AgRP]) and upregulate anorexigenic signals ( Pro-opiomelanocortin [POMC] ) in the arcuate nucleus of the hypothalamus.
Pharmacotherapeutic & Orexigenic Landscape
Drug Class & Agent Typical Daily Dosage Primary Efficacy & Mechanism of Action Body Composition Impact & Critical Safety Warnings
Progestins ; (Megestrol Acetate / Megace) 400 to 800 mg/day oral suspension Stimulates hypothalamic NPY release; downregulates inflammatory cytokines. Increases fat mass and fluid retention ONLY (no skeletal muscle gain). Black Box Warnings: Deep vein thrombosis (DVT), PE, peripheral edema, hypogonadism, adrenal suppression .
Corticosteroids ; (Dexamethasone) 4 mg/day oral (or Prednisone 0.75 mg/kg) Central CNS stimulation; suppression of prostaglandin synthesis and cytokine release. STRICTLY LIMIT TO <2–3 WEEKS . Prolonged use causes severe steroid myopathy (accelerates muscle wasting) , hyperglycemia, infections, and insomnia.
Cannabinoids ; (Dronabinol / Δ 9 \Delta^9 Δ 9 -THC) 2.5 to 5 mg BID (1h before lunch & dinner) Activates central cannabinoid C B 1 CB_1 C B 1 receptors in hypothalamus and limbic system. Mild appetite stimulation. Causes somnolence, dizziness, euphoria, dysphoria, and confusion (caution in elderly).
Atypical Antipsychotics ; (Olanzapine) 2.5 to 5 mg/day at bedtime Broad multi-receptor blockade ( D 2 , 5 -HT 2 c , 5 -HT 3 , H 1 D_2, 5\text{-HT}_{2c}, 5\text{-HT}_3, H_1 D 2 , 5 -HT 2 c , 5 -HT 3 , H 1 ). Improves appetite, promotes weight gain, controls nausea, and reduces anxiety. Causes sedation and dry mouth.
Antidepressants ; (Mirtazapine) 15 to 30 mg/day at bedtime Dual H 1 H_1 H 1 -histamine antagonist (sedating) and 5 -HT 2 c 5\text{-HT}_{2c} 5 -HT 2 c antagonist (orexigenic). Excellent for triad of anorexia + insomnia + depression . Promotes weight gain; causes daytime somnolence.
Ghrelin Agonists ; (Anamorelin - Investigational) 100 mg/day oral Selective oral agonist of growth hormone secretagogue receptor (GHSR-1a). Increases lean body mass , total body weight, and appetite. High safety profile; mild hyperglycemia risk.
- In-Depth Clinical Evaluation of Orexigenic Agents
- 1. Megestrol Acetate (Megace)
Megestrol acetate is an oral synthetic progestin. While randomized controlled trials demonstrate significant increases in subjective appetite and total body weight, sophisticated body composition analyses (DEXA, CT body composition) reveal that weight gain consists almost exclusively of adipose tissue and fluid retention , with zero gain in skeletal muscle mass. Megestrol acetate carries severe thromboembolic risks (DVT/PE rate ~5%) and causes secondary adrenal suppression due to intrinsic glucocorticoid activity. It is strictly contraindicated in patients with a history of VTE.
2. Corticosteroids (Dexamethasone)
Dexamethasone produces rapid, dramatic improvements in appetite, energy, and sense of well-being within 24–48 hours. However, its orexigenic response wanes significantly after 3–4 weeks. Therapy MUST be restricted to short-term use (<2 to 3 weeks) or reserved for end-of-life palliative care. Chronic administration triggers severe steroid-induced myopathy (muscle catabolism), exacerbating the very muscle wasting CACS produces, alongside severe hyperglycemia, osteopenia, and immunosuppression.
3. Mirtazapine & Olanzapine in Supportive Care
Mirtazapine: Uniquely suited for cancer patients presenting with the clinical triad of anorexia, depression, and insomnia . Sedating H 1 H_1 H 1 blockade taken at bedtime promotes restful sleep, while 5 -HT 2 c 5\text{-HT}_{2c} 5 -HT 2 c blockade stimulates morning appetite.
Olanzapine: Clinical trial data support 5 mg daily olanzapine for significantly enhancing appetite and weight gain while simultaneously suppressing nausea and anxiety in advanced cancer.
4. Omega-3 Fatty Acids (EPA) & Targeted Nutritional Therapeutics
Eicosapentaenoic Acid (EPA): High-dose EPA (2.0 g/day) downregulates NF- κ \kappa κ B transcription, reducing pro-inflammatory cytokine production and inhibiting the Ubiquitin-Proteasome System, helping stabilize lean muscle mass in inflammatory cachexia.
High-Protein MNT Integration: Orexigenics must be paired with 1.5 to 2.0 g protein/kg/day and high-calorie ONS to provide essential amino acids for muscle protein synthesis.
Clinical Case & Decision Tree
Patient Profile: A 66-year-old male with Stage IV pancreatic cancer presents with 10% weight loss over 8 weeks, severe anorexia, early morning insomnia, and mild depression. Medical history includes a deep vein thrombosis (DVT) 6 months ago treated with apixaban.
Pharmacotherapy Selection Analysis:
Contraindication Check: Megestrol acetate is CONTRAINDICATED due to his prior history of DVT.
Short-Term vs. Long-Term Need: Dexamethasone is inappropriate for long-term management (>3 weeks) due to muscle myopathy risk.
Optimal Choice: Mirtazapine (15 mg at bedtime) is the ideal targeted agent, addressing his anorexia, insomnia, and depression simultaneously without VTE or myopathy risks. Pair with EPA 2.0 g/day and high-protein ONS.